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LETTERS TO THE EDITOR
Prevalence of
hyperhomocysteinemia in
male hemodialysis patients
To the Editor: The risk for vascular disease is much
higher in hemodialysis patients than in the general popula-
tion [1]. Sex, hypertension, diabetes mellitus, being over-
weight, hyperlipidemia, hyperhomocysteinemia, and smok-
ing are well-established risk factors of cardiovascular
disease [2–3]. This study was undertaken to define the
influence of sex on the prevalence of conventional risk
factors in 54 long-term hemodialysis patients: 24 female,
30 male (mean age in years, 60  12 female and 65 
15 male; mean dialytic age in months, 59  48 female
and 61  55 male). All patients received thrice-weekly
dialysis and ratio of urea clearance times dialysis dura-
tion to the volume that the urea is distributed in (Kt/v)
was always 1.2. No patients at the time of the study
were receiving folate or vitamin B supplements. To-
tal homocysteine (Hcy) was tested by a standard high-
performance liquid chromatography (HPLC) assay and
the following biochemical parameters were also tested:
albumin (g/L), cholesterol (mg/dL), and triglycerides
(mg/dL). Male hemodialysis patients showed signifi-
cantly higher Hcy levels when compared to female hemo-
dialysis patients (66.8  49.1 vs. 40.6  21.7, P  0.02).
Mean plasma—cholesterol (200  40 males vs. 201 
46 females); triglycerides (204  126 males vs. 163  64
females); and albumin (20.0  40.3 males vs. 20.1 
46.2 females) did not show any statistical difference. The
prevalence of hypertension defined as blood pressure
140/80 mm Hg and smoking was similar between the
two groups (76% males vs. 69% females). To our knowl-
edge, this is the first observation of a significant differ-
ence between male and female serum Hcy levels. This
finding may account for the different cardiovascular risk
between the 2 populations of HD patients. Therapeutic
approaches aimed to treat hyperhomocysteinemia should
take into account different cut-off points according to
gender.
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Vitamin C in renal failure—
Pro- or antioxidant?
To the Editor: We observed that vitamin C improved
endothelial function in the resistance vasculature of pa-
tients with chronic renal failure, and that this effect was
abolished by an inhibitor of nitric oxide (NO) synthesis
(l-NMMA). In the current investigation, no intravenous
iron was given in the 4 weeks preceding the study. We
allude to the possible pro-oxidant effect of vitamin C
in the discussion, and it is possible that there may be
heterogenous effects of vitamin C on oxidative stress in
these patients. However, a pro-oxidant effect of vitamin
C in the presence of iron is not consistently observed in
biologic systems. Berger et al [1] demonstrated that in
iron-overloaded plasma, high concentrations of vitamin
C prevented lipid oxidation and was not responsible for
protein or lipid peroxidation in vivo. Proteggenette et al
[2] found no evidence for a pro-oxidant effect on DNA
base pair damage after vitamin C supplementation, in the
presence or absence of iron.
We did not measure blood pH during infusion of vita-
min C so we cannot be certain if it caused local or systemic
acidosis. However, if a substantial change in pH were to
contribute to the enhanced vasodilatation to acetylcholine,
we would expect that it would have been present when
vitamin C was infused alone, would have occurred when
vitamin C was co-infused with the NO donors, and would
have been resistant to the effects of l-NMMA. We did
not observe these nonspecific effects of vitamin C and
think that increased NO bioactivity is the most likely ex-
planation of our findings.
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Estimating protein intake
in maintenance
hemodialysis patients
To the Editor: We have read with interest the paper in
a recent issue of Kidney International by Masud et al [1]
on the precision of estimating the protein intake in chronic
renal failure (CRF). The authors provide evidence that
the amount of protein intake does not reflect the excretion
of fecal nitrogen; thus, fecal nitrogen, even if correlated
with body weight, does not influence the measurement
of protein intake in stable CRF patients. The accurate
estimation of protein intake is even more crucial in hemo-
dialysis (HD) patients because of the greater risk of mal-
nutrition. In clinical practice, protein intake is usually
estimated in HD by the calculation of protein nitrogen
appearance (PNA) derived from the urea nitrogen ap-
pearance (UNA) during the interdialytic period [2]. To
note, the effect of fecal nitrogen excretion on the mea-
surement of protein intake and the influence of different
amount of eaten protein on the fecal excretion of nitro-
gen, as well, have not been previously evaluated.
We analyzed 139 series of three-day period daily pro-
tein intakes measured during the long interdialytic inter-
val. The mean interdialytic protein intake estimated by
PNA was 1.26  0.28 g/kg body weight/day (range, 0.66
to 2.18), while the daily protein intake progressively de-
creased from 1.50  0.43 to 1.32  0.35 and to 1.00 
0.34 g/kg body weight/day (P  0.001) during the three-
day period (range, 0.71 to 2.91, 0.49 to 2.29, and 0.22 to
1.82, respectively, on the 1st, 2nd, and 3rd day). Twenty-
seven patients (age, 32 to 70 years; body weight, 52 to
78 kg) collected the daily feces during the same time
period in order to measure the fecal nitrogen excretion.
At variance with UNA, which gradually dropped, fecal
nitrogen (FN) remained unchanged during the interdia-
lytic period (Fig. 1). Fecal nitrogen excretion was remark-
ably stable during the study, measuring 5.0 mg/kg body
weight/day (range, 4.0 to 6.6) on each of the 3 days (NS);
the coefficient of variation was lower than 3% (range,
0.5 to 4.0).
In HD patients, variations of eaten protein do not
affect the fecal excretion of nitrogen; therefore, in these
patients, as demonstrated in CRF [1], fecal nitrogen does
not influence the measurement of protein intake.
Fig. 1. Daily measurement of urea nitrogen appearance (UNA) ()
and fecal nitrogen excretion (FN) ( ) in chronic hemodialysis patients
during the long interdialytic period. *P  0.05 vs. 1; P  0.05 vs. 2.
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Plasma level of soluble Fas is
an independent marker of
cardiovascular disease in
ESRD patients
To the Editor: In the October 2002 issue of Kidney
International, Caglar K et al [1] discussed the potential
inflammatory role of hemodialysis (HD) in end-stage re-
nal disease (ESRD) patients. Evidence suggests that apo-
ptotic endothelial cells are present at sites of atherosclero-
sis plaques [2]. To evaluate the association between
inflammation, endothelial apoptosis, and cardiovascular
(CV) morbidity and mortality in ESRD patients, we have
measured plasma level of soluble Fas (sFas) was measured
by enzyme-linked immunosorbent assay (ELISA) in a
cross-sectional analysis [3]. Eighteen chronic HD patients,
9 non-HD ESRD patients (CrCl, 10.3 2.4 mL/min), and
15 age- and sex-matched healthy subjects (CrCl, 98.4 3.5
